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Abstract 
Purpose: To investigate the effect of Artemesia annua extract on glyoxal-induced injury in retinal 
microvascular endothelial cells (HRECs).  
Methods: HRECs were cultured in a medium containing 500 µM glyoxal or glyoxal plus 50µM 
Artemesia annua extract, or in the medium alone for 24 h. Apoptosis was analysed by flow cytometry 
using annexin V and propidium iodide staining. Changes in mitochondrial membrane potential were 
determined by JC-1 staining. 
Results: When HRECs were cultured in a medium of 500 µM glyoxal, a significant (p < 0.05) decrease 
in caspase-3 expression was observed. However, treatment of HRECs with Artemesia annua extract 
(50 µM) inhibited the glyoxal-mediated decrease in caspase-3 expression. The extract also inhibited 
caspase-3 proteolysis, as was evident from the reduction in the level of cleaved caspase-3. Up-
regulation of ROS production by glyoxal in HRECs was inhibited by treatment with the extract. The 
viability of HRECs was significantly decreased by glyoxal (p < 0.05), but the decrease in viability was 
significantly reversed by Artemesia annua extract (p < 0.05). The extract also reduced gyloxal-induced 
apoptosis in HRECs from 17.3 to 2.6 % (p < 0.001). Results from JC-1 staining showed significantly (p < 
0.001) higher level of green fluorescence in HRECs cultured with glyoxal. However, the glyoxal-induced 
increase in green fluorescence level was significantly (p < 0.01) reduced on exposure to Artemesia 
annua extract.  
Conclusion: Artemesia annua extract prevents oxidative damage to HRECs via inhibition of ROS 
production, up-regulation of caspase-3 expression and suppression of caspase-3 proteolysis. Therefore, 
Artemesia annua can potentially be used for the development of a new drug for the prevention of retinal 
injury in glaucoma.  
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Diabetic retinopathy is a common cause of vision 
loss in people with diabetes mellitus throughout 
the world [1]. It causes cellular degradation of 
retina, and is characterised by hyperglycaemia 
[1]. The level of glyoxal, which is a toxic 
chemical, increases during hyperglycaemia,  
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leading to oxidative damage through up-
regulation of generation of reactive oxygen 
species (ROS) [2,3]. In hyperglycaemic patients, 
the development of diabetic retinopathy is 
facilitated by ROS production through increased 
capillary permeability [4-6]. The high level of 
blood glucose promotes O-linked β-N-acetyl 
glucosamine expression which plays a crucial 
role in the development of diabetes [7,8].  
 
High intraocular pressure is considered a major 
pre-disposing factor for glaucoma, and it leads to 
optic nerve shrinkage and retinal ganglion cell 
apoptosis [9-11]. This disorder cannot be 
remedied even after transplantation of stem cells 
or ganglion cells [9,12]. Current treatments for 
glaucoma focus mainly on neuro-protection. 
Identification of novel and efficient neuro-
protective agents is of immense importance for 
the prevention of retinal injury during glaucoma. 
Studies have been carried out to investigate the 
protective effects of various compounds against 
retinal injury during glaucoma in animal models. 
The extracts which have been investigated in 
animal models for this purpose include Lycium 
barbarum Lynn and Salvia miltiorrhiza [13-16]. 
 
In the present study, the effect of Artemesia 
annua extract on the viability of HRECs was 
investigated. Glyoxal was added to HRECs 
cultures to induce oxidative stress, and the 





Culturing of HRECs 
 
The HRECs were obtained from Cell Systems 
Corp. (CSC; Kirkland, WA, USA) and expression 
of ROS was analysed by immunofluorescence 
staining. The cells were grown in DEM medium 
containing 5 % FBS and 1 % penicillin and 
streptomycin in an atmosphere of 5 % CO2 at a 
temperature of 37 ˚C. 
 
Western blot assay 
 
The HRECs were cultured in a medium 
containing 500 µM glyoxal alone (control) or 
glyoxal and Artemesia annua extract (50 µM) for 
24h, and washed twice with phosphate-buffered 
saline (PBS). The cells were then treated with 
lysis buffer supplemented with protease inhibitor 
cocktail. The proteins from the cell extract were 
separated by subjecting equal amounts (30 µg) 
to fractionation on 10 % polyacrylamide gel. The 
separated proteins were subsequently 
transferred at 200 mA to polyvinylidene fluoride 
membranes for 2 h. The membranes were 
blocked by incubation with 0.05 % non-fat milk 
powder in TBST for 2h at 37 ˚C.  After blocking, 
the membranes were incubated with primary 
antibodies overnight at 4 ˚C.  
 
The antibodies used were rabbit anti-caspase-3 
(catalog no. 9665; dilution 1: 1, 000) and anti-β-
actin (catalog no. 8457; dilution 1:1,000; both 
from Cell Signalling Technology; Danvers, MA, 
USA). After incubation, the blots were washed 
twice with PBS-T (0.1 % Tween-20 in PBS), and 
then incubated with goat horseradish peroxidase-
conjugated anti-mouse IgG (dilution 1: 5, 000; 
Pierce Biotechnology, Rockford, IL, USA) 
secondary antibody at room temperature for 1h. 
The blots were thereafter visualized under 
Odyssey (LI-COR Biosciences, Lincoln, NE, 
USA). 
 
Analysis of ROS production 
 
Analysis of ROS production in HRECs was 
carried out using DCFH-DA. Into the cell 
cultures, 5 µM of DCFH-DA was added and the 
cells were cultured for 30 min, and then lysed 
using sodium hydroxide (400 mM) for 2 h at room 
temperature. The lysates were used for 
determination of ROS production by measuring 
the intensity of fluorescence at absorption and 
emission wavelengths of 480 and 430 nm, 
respectively in a multi-well plate reader (Synergy 
2, BioTek Instruments Inc., Winooski, VT, USA). 
Bicinchoninic acid (BCA) protein assay kits 
(Pierce Biotechnology) were used for protein 
determination. Quantification was performed as 
the ratio of the intensity of fluorescence to 
concentration of protein. 
 
Evaluation of cell viability 
 
The HRECs were seeded into 96-well culture 
plates at a density of 1 x 104 cells per well and 
cultured for 24 h under an atmosphere of 5 % 
CO2 at 37 ˚C. The cells were then assigned to 
three groups: one group was cultured in a 
medium containing 500 µM glyoxal; the second 
group was cultured in a medium containing 500 
µM glyoxal and 50 µM Artemesia annua extract, 
while the third group (normal control) was 
cultured in medium alone. After 24 h, CCK-8 
solution (10 µL) was added to the plates and 
incubation was continued further for 4 h.  
 
At the end of incubation, the absorbance for each 
plate was recorded three times in a multi-well 
plate reader at 450 nm. The effect of hydrogen 
peroxide on HRECs viability was analysed on 
incubation with 200 µM H2O2 in the medium 
containing 5 % of FBS.  
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Flow cytometry analysis 
 
The cells were cultured in a medium containing 
500 µM glyoxal or glyoxal (500 µM) plus 
Artemesia annua extract (50 µM), or medium 
alone, for 24 h. After incubation, the cell pellet 
was re-suspended in binding buffer, and 
incubated with 5 ml of Annexin V (conjugated 
with FITC; BD Biosciences) and 10 ml of PI (BD 
Biosciences), in the dark for 5 min. Finally, the 
cells were examined in a FACScan flow 
cytometer (Becton-Dickinson, Franklin Lakes, 
NJ, USA). 
 
Determination of mitochondrial membrane 
potential 
 
In the analysis of changes in mitochondrial 
membrane potential, JC-1 stain was used. The 
three groups of cells cultured in different media 
as outlined earlier, were analysed for changes in 
membrane potential. The cells were stained with 
JC-1 (2.5 µM) for 20 min at 37 ˚C, and 
subsequently rinsed thrice in PBS. Images were 
captured at 525 nm and 557 nm absorption and 
emission wavelengths, respectively, using an 
inverted fluorescence microscope (Leica 
Microsystems). The intensity of fluorescence was 




The experimental data are expressed as mean ± 
standard deviation (SD). Statistical analysis was 
performed with SPSS 13.0 statistical software 
(SPSS, Inc. Chicago, IL, USA). One-way 
analysis of variance (ANOVA) was used, 
followed by Dunnett's test for multiple 
comparisons. P < 0.05 was considered to 




Effect of Artemisia annua on expression of 
caspase-3 in HPRECs 
 
Glyoxal caused a significant decrease in the 
expression of caspase-3 in HRECs. However, 
treatment of the glyoxal-exposed HRECs with 
Artemesia annua extract led to a significant (p < 
0.01) increase in caspase-3 expression (Figure 
1). Proteolysis of caspase-3 was inhibited by 
Artemesia annua extract, as was evident in 
reduction of the level of cleaved caspase-3. 
These findings suggest that Artemesia annua 





Figure 1: Artemesia annua extract inhibited glyoxal-
induced cleavage of caspase-3 in HRECs. The 
quantification of caspase-3 level in HRECs following 
treatment with glyoxal and/or Artemesia annua extract 
was performed using Quantity One software. *p < 0.05 
(glyoxal vs. normal control); **p < 0.01 (glyoxal vs. 
glyoxal + Artemesia annua extract) 
 
Artemesia annua extract inhibited production 
of ROS in glyoxal-treated HRECs 
 
Examination using fluorescence microscopy 
showed higher intensity of bright spots in HRECs 
treated with glyoxal, when compared to untreated 
HRECs (Figure 2). The ROS production induced 
by glyoxal in HRECs was inhibited by treatment 
with Artemesia annua extract (p < 0.05). 





Figure 2: Artemesia annua extract blocked up-regulation of ROS production by glyoxal. HRECs, after treatment 
with glyoxal and/or Artemesia annua extract, were analysed for ROS content by fluorescence microscopy using 
DCFH-DA staining. An automatic microplate reader was used for quantitative analysis of changes in ROS 
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Figure 3: Artemesia annua extract prevented glyoxal-mediated loss of viability in HRECs. *p < 0.005 
(glyoxal vs. control); **p > 0.05 (glyoxal vs glyoxal + Artemesia annua extract). HRECs were exposed 
to H2O2 and then treated with Artemesia annua extract for 24 h. #p < 0.001 (H2O2 vs. normal control); 




Figure 4: Artemesia annua extract prevented glyoxal-induced apoptosis in HRECs. Flow cytometry was used to 
determine the effect of glyoxal and Artemesia annua extract on apoptosis in HRECs after 24 h. Staining of 
HRECs was performed using Annexin V-FITC and PI, followed by FACS  
  
Artemesia annua extract prevented glyoxal-
mediated decrease in viability of HRECs 
 
Changes in viability of HRECs treated with 
Artemesia annua extract were analysed after 
24h. Glyoxal treatment led to a significant (p < 
0.005) decrease in HRECs viability, when 
compared to the untreated control (Figure 3). 
However, after Artemesia annua extract 
treatment, the viability of HRECs exposed to 
glyoxal was significantly increased. In order to 
confirm if Artemesia annua extract prevented 
inhibition of viability through attenuation of 
oxidative damage, HRECs were treated with 
H2O2 (200 µM) for 2 h. The results showed that 
H2O2 reduced HRECs viability, but the inhibitory 
effect was reversed by Artemesia annua extract 
(Figure 3). 
 
Artemesia annua extract blocked apoptosis in 
HRECs  
 
Glyoxal treatment increased the percentage of 
apoptosis in HRECs to 17.3 %, when compared 
to 2.5 % in the untreated control (Figure 4). 
However, addition of Artemesia annua extract to 
the glyoxal-treated cultures of HRECs led to 
significant reduction of apoptosis to 2.6 % 
(Figure 4). Thus, it is clear that Artemesia annua 
extract prevented glyoxal-mediated increase in 
the percentage of apoptosis in HRECs. 
 
Artemesia annua extract prevented glyoxal-
mediated alteration in mitochondrial 
membrane potential 
 
The results from JC-1 probe showed a 
significantly higher level of green fluorescence in 
HRECs cultured with glyoxal (Figure 5). 
However, the level of green fluorescence was 
significantly reduced in glyoxal-treated HRECs 
on exposure to Artemesia annua extract (Figure 
5). These observations suggest that Artemesia 
annua extract blocked changes in mitochondrial 




Reactive oxygen species (ROS) are responsible 
for cellular stress that results in retinal injury and 
loss of vision [5,17,18]. Increased blood glucose 
levels for prolonged durations at the initial stage  
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Figure 5: Effect of Artemesia annua extract on glyoxal-induced changes in mitochondrial membrane potential in 
HRECs. The cells were incubated with JC-1 after treatment with glyoxal and Artemesia annua extract for 24 h. 
Inverted fluorescent microscope and Image-Pro Plus software were used for measurement of fluorescence. The 
loss in membrane potential in cells treated with glyoxal was prevented by addition of Artemesia annua extract 
 
of diabetic retinopathy result in generation of 
ROS and the development of retinal hypoxia [19]. 
Studies have shown that following surgical eye 
treatment in patients with proliferative diabetic 
retinopathy, the expression of hypoxia-inducible 
factor (HIF)-1α is high in vitreous fluid [20]. Up-
regulation of HIF-1α expression is a 
characteristic feature of hypoxia and onset of 
oxidative damage [21]. Exposure of HRECs to 
glyoxal leads to marked increases in the rate of 
apoptosis [22]. It has been reported that the 
suppression of ROS production inhibits apoptosis 
and increases the viability of HRECs [22]. 
Indeed, several studies have shown that the 
production of ROS plays a vital role in the 
development of retinal injury and diabetic 
retinopathy [23-26]. 
 
The results of the present study showed that 
Artemesia annua extract inhibited glyoxal-
induced ROS generation in HRECs. Apoptosis in 
endothelial cells which form lining of the capillary 
wall plays a vital role in the onset of diabetic 
retinopathy. The present study has demonstrated 
that glyoxal-mediated increase in apoptosis in 
HRECs was significantly inhibited by Artemesia 
annua extract. In order to understand the 
mechanism of Artemesia annua extract-mediated 
blockage of glyoxal-induced apoptosis in HRECs, 
caspase-3 and mitochondrial membrane 
potential were determined. Increases in the level 
of cleaved caspase-3 enhance the rate of 
apoptosis in HRECs. Caspase-3 is activated by 
proteolysis into cleaved caspase-3 which has an 
important role in inducing apoptosis [27-29]. 
Glyoxal treatment has been shown to increase 
the level of cleaved caspase-3 level and 
decrease overall caspase-3 activity in HRECs 
after 24 h [28, 29]. In the current study, the 
addition of Artemesia annua extract to the 
glyoxal-treated cultures of HRECs led to 
increased level of caspase-3. In presence of 
glyoxal, treatment of HRECs with Artemesia 
annua extract prevented reduction in viability. In 
order to confirm the anti-oxidative mode of action 
of Artemesia annua extract in blocking glyoxal-
mediated loss of viability, HRECs were treated 
with H2O2. The results revealed that the H2O2-
induced reduction in HREC viability was inhibited 
by the extract. Thus, Artemesia annua extract 
acted as a therapeutic agent for prevention of 
apoptosis in HRECs through a mechanism 
involving targeting of ROS production. 
 
Mitochondria play important roles in the 
protection of cellular damage by inhibiting ROS 
production, and regulating calcium ion channels 
[30,31]. In the present study, results from JC-1 
staining and inverted fluorescent microscopy 
showed that Artemesia annua extract prevented 
changes in mitochondria membrane potential 




The findings of the present study provide indicate 
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that Artemesia annua extract prevents glyoxal-
induced apoptosis in HREC by inhibition of ROS 
production and blockage of caspase-3 cleavage. 
The extract also prevents changes in 
mitochondrial membrane potential. Thus, 
Artemesia annua has potentials to be developed 
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